Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
4(27%)
Results Posted
40%(4 trials)

Phase Distribution

Ph phase_2
1
7%
Ph phase_1
12
80%
Ph phase_3
2
13%

Phase Distribution

12

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
12(80.0%)
Phase 2Efficacy & side effects
1(6.7%)
Phase 3Large-scale testing
2(13.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

15

all time

Status Distribution
Active(5)
Completed(10)

Detailed Status

Completed10
Recruiting3
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 112 (80.0%)
Phase 21 (6.7%)
Phase 32 (13.3%)

Trials by Status

recruiting320%
completed1067%
not_yet_recruiting17%
active_not_recruiting17%

Recent Activity

4 active trials
Showing 5 of 15
active_not_recruitingphase_1

A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527-020)

NCT07528508
not_yet_recruitingphase_1

A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)

NCT07600775
recruitingphase_3

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

NCT07044297
recruitingphase_3

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

NCT07071623
recruitingphase_1

A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)

NCT07661108
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT07528508Phase 1

A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527-020)

Active Not Recruiting
NCT07600775Phase 1

A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)

Not Yet Recruiting
NCT07044297Phase 3

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Recruiting
NCT07071623Phase 3

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Recruiting
NCT07661108Phase 1

A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)

Recruiting
NCT06580587Phase 1

A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)

Completed
NCT07025551Phase 1

A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015)

Completed
NCT06295796Phase 1

A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

Completed
NCT07063238Phase 1

A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)

Completed
NCT06045507Phase 2

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

Completed
NCT06893081Phase 1

A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)

Completed
NCT06816043Phase 1

A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants

Completed
NCT05494736Phase 1

MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

Completed
NCT06783192Phase 1

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

Completed
NCT03615183Phase 1

A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15